Predictors and Consequences of Serious Adverse Events in Patients Treated With Thrombolysis: A Prespecified Secondary Analysis of the AcT Trial

Journal of the American Heart Association 2026 Open access

Read full text
Authors: Aria Appoo, Katrina Hannah D. Ignacio, Cody Doolan, Fouzi Bala, Mohammed A Almekhlafi, Brian H. Buck, Aleksander Tkach, Luciana Catanese, Richard H. Swartz, Tolulope T. Sajobi, Aravind Ganesh, Bijoy K. Menon
+1 more Nishita Singh
DOI: 10.1161/jaha.125.048280
Cited by: 1
References: 21

Abstract

BACKGROUND: With the increasing use of tenecteplase, it is important to understand its safety compared with alteplase. We aimed to determine the incidence, predictors, and functional impact of serious adverse events (SAEs) in patients treated with alteplase versus tenecteplase. METHODS: This is a post hoc analysis of the AcT (Alteplase Compared to Tenecteplase) trial, a phase 3 multicenter randomized controlled trial that randomized 1577 ischemic patients with stroke (2019-2022) into tenecteplase versus alteplase presenting

Fields of Study & Subjects

Acute Ischemic Stroke Management Stroke Rehabilitation and Recovery Intracerebral and Subarachnoid Hemorrhage Research

Publication details

Journal / source
Journal of the American Heart Association
Publisher
Ovid Technologies (Wolters Kluwer Health)
Volume
15
Issue
12
Pages
e048280–e048280
Publication date
9 June 2026
Language
EN